Download presentation
Presentation is loading. Please wait.
Published byTine Gabrielsen Modified over 5 years ago
1
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
Linda L. Garland, MD, Kari Chansky, MS, Antoinette J. Wozniak, MD, Anne S. Tsao, MD, Shirish M. Gadgeel, MD, Claire F. Verschraegen, MD, Marco A. DaSilva, MD, Mary Redman, PhD, David R. Gandara, MD Journal of Thoracic Oncology Volume 6, Issue 11, Pages (November 2011) DOI: /JTO.0b013e e Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
2
FIGURE 1. A and B, Computed tomography scans of the thorax over the course of cediranib therapy. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e e) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
3
FIGURE 2. Waterfall plot of best response.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e e) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
4
FIGURE 3. Progression-free survival.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e e) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
5
FIGURE 4. Overall survival.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e e) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.